|
Volumn 9, Issue 11, 2009, Pages 2445-2446
|
Belatacept results promising... with some caveats
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BELATACEPT;
CYCLOSPORIN A;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
RAPAMYCIN;
T LYMPHOCYTE RECEPTOR;
TACROLIMUS;
THYMOCYTE ANTIBODY;
ABATACEPT;
ANTIBODY CONJUGATE;
IMMUNOSUPPRESSIVE AGENT;
ANTIGEN PRESENTING CELL;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CYTOMEGALOVIRUS INFECTION;
DRUG MECHANISM;
DRUG SAFETY;
EPSTEIN BARR VIRUS;
HUMAN;
KIDNEY FUNCTION;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LYMPHOPROLIFERATIVE DISEASE;
MAJOR HISTOCOMPATIBILITY COMPLEX;
MALIGNANT NEOPLASTIC DISEASE;
PRIORITY JOURNAL;
SHORT SURVEY;
GRAFT REJECTION;
NOTE;
TRANSPLANTATION;
GRAFT REJECTION;
HUMANS;
IMMUNOCONJUGATES;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY TRANSPLANTATION;
TISSUE AND ORGAN PROCUREMENT;
|
EID: 70350129074
PISSN: 16006135
EISSN: 16006143
Source Type: Journal
DOI: 10.1111/j.1600-6143.2009.02866.x Document Type: Short Survey |
Times cited : (4)
|
References (1)
|